NCT02099474已完成2 期
Evaluation of the Pharmacokinetic Properties and the Tolerance of Raltegravir During the Third Trimester of Pregnancy
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 83
- 试验地点
- 2
- 主要终点
- Comparison of the AUC and raltegravir trough concentration during and after pregnancy
研究概览
简要总结
The purpose of this study is to assess the evolution of raltegravir concentration in the mother (between the 3rd trimester of pregnancy and one month post-delivery) and her neonate, when this drug is used to prevent mother-to-child HIV-1 transmission as part of a combined antiretroviral regimen.
详细描述
-
Objectives
-
Principal objective
- To study pharmacokinetic properties of raltegravir in pregnant women infected by HIV-1, during the third trimester of pregnancy (between 30 and 37 weeks of amenorrhea) and 1 month after childbirth (between W4 and W6 postpartum), as well as in their neonate.
- Secondary objectives
- Estimate the frequency of women receiving raltegravir and having indetectable viral load at delivery (and those having a strictly indetectable viral load, with no signal under the threshold of the technique used).
- Describe the tolerance to raltegravir in pregnant women during the third trimester and in her neonates
- Methodology
- National multicenter pharmacokinetic study conducted among pregnant women infected by HIV-1 and exposed to raltegravir during pregnancy.
- Statistical method
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Pregnant woman, between 30 and 37 weeks of amenorrhea
- •18 years old and over
- •Infected by HIV-1
- •Receiving a therapeutic combination, stable for at least 15 days before inclusion, with raltegravir at the standard dose (400 mg twice daily) which the doctor plans to maintain till the end of pregnancy and at least one month after delivery
- •Informed consent signed by mother and investigator (at the latest day of pre-inclusion and before any examination conducted as part of research)
- •Affiliated person or beneficiary of a social security system (medical aid of state or AME is not a social security system)
- •Participant agreeing to be registered in the national file of the people who participate in biomedical researches
排除标准
- •Infected by HIV-2
- •Under 18 years old
- •Receiving therapeutic association with atazanavir (Reyataz®), fosamprenavir (Telzir®), or efavirenz ( contained in Sustiva® and Atripla®)
- •Currently using medication, drugs or alcohol which can interfere with the research: rifampicine, phénobarbital, phénytoïne, topical gastrointestinal, antiacid and adsorbents
- •Presenting a clinical situation or acute pathology incompatible with the realisation of a pharmacokinetic study.
- •Planned absence which could hinder research participation (travel abroad, moving, imminent transfer ...)
- •Participating in another research, except the French perinatal survey (ANRS CO1 EPF or ANRS CO11 observatory), including an exclusion period still in progress at the pre-inclusion
- •Person under guardianship, or deprived of freedom by a judicial or administrative decision
结局指标
主要结局
Comparison of the AUC and raltegravir trough concentration during and after pregnancy
时间窗: 5 samples: before the drug intake, 0.5, 3, 8 and 12 hours after the intake at each of the 2 visits (between 30 and 37 weeks of amenorrhea, and 4 to 6 weeks after delivery)
次要结局
- Study of genetic polymorphism which could modify raltegravir concentrations(Up to 72 hours after delivery)
- Proportion of maternal-to-child HIV transmission(Up to 72 hours after delivery)
- Estimation of neonatal elimination of raltegravir(Up to 72 hours after delivery)
- Estimation of placental transfer of raltegravir(Up to 72 hours after delivery)
- Untimely stop of raltegravir for toxicity or intolerance(Up to 72 hours after delivery)
- Proportion of women having a viral load < 50 cp/mL at delivery(Up to 72 hours after delivery)
- Clinical and biological anomaly occurring during the third trimester of pregnancy and during the first 6 months of life of the neonate.(Month 6)
研究者
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Evaluating the Safety and Pharmacokinetics of Raltegravir in InfantsHIV InfectionsNCT01828073National Institute of Allergy and Infectious Diseases (NIAID)40
撤回
不适用
Pharmacokinetics, Pharmacodynamics and Cervicovaginal Lavage of Combined Oral Contraceptives and RaltegravirHIVNCT01597180University of North Carolina, Chapel Hill
已完成
不适用
Levels of Raltegravir in the Female Genital TissueHIVNCT01327482University of Washington10
已完成
1 期
TMC278-TiDP6-C153 - A Study in Healthy Volunteers Investigating the Pharmacokinetic Interaction Between TMC278 and RaltegravirHIV InfectionsNCT01288755Tibotec Pharmaceuticals, Ireland24
已完成
4 期
Plasma and Intracellular Concentrations of Raltegravir and Etravirine Administered Once DailyHIV-1 InfectionHIV InfectionsNCT01121809Hospitales Universitarios Virgen del Rocío16